NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris VTRS.O and Mapi Pharma's once-a-month injection for treating relapsing forms of multiple sclerosis (MS), the companies said on Monday.

Patients treated with interferon beta (IFNb) who have experienced loss of efficacy due to the development of neutralizing antibodies, had a significant delay in time to first relapse following switch ...

Copaxone and its generic form, Glatopa, may lead to anaphylaxis even in patients who’ve been taking the medication for months without incident. The FDA warns that the injectable MS drugs Copaxone and ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its ...

About 400,000 Americans have multiple sclerosis, and up until now, the only drugs offered to them to slow the course of the disease had to be injected or dripped into a vein. But soon, it seems, they ...

March 11 (Reuters) - The U.S. FDA has declined to approve Viatris (VTRS.O), opens new tab and Mapi Pharma's once-a-month injection for treating relapsing forms of debilitating neurological condition ...